These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 26415700)

  • 21. Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study.
    Wohl DA; Dumond JB; Blevins S; Pittard D; Ragan D; Wang R; Massengale K; Walsh K; Floris-Moore M; Eron JJ; Richardson A; Hudgens MG; Kashuba AD
    Antimicrob Agents Chemother; 2013 Feb; 57(2):784-8. PubMed ID: 23183440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.
    Calcagno A; D'Avolio A; Bonora S
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1167-76. PubMed ID: 26073580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot study.
    Calza L; Magistrelli E; Colangeli V; Borderi M; Conti M; Mancini R; Viale P
    Antivir Ther; 2016; 21(3):217-24. PubMed ID: 26405177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
    Cahn P; Kaplan R; Sax PE; Squires K; Molina JM; Avihingsanon A; Ratanasuwan W; Rojas E; Rassool M; Bloch M; Vandekerckhove L; Ruane P; Yazdanpanah Y; Katlama C; Xu X; Rodgers A; East L; Wenning L; Rawlins S; Homony B; Sklar P; Nguyen BY; Leavitt R; Teppler H;
    Lancet HIV; 2017 Nov; 4(11):e486-e494. PubMed ID: 28918877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual Raltegravir-Etravirine Combination as Maintenance Regimen in Virologically Suppressed HIV-1-Infected Patients.
    Calza L; Magistrelli E; Colangeli V; Manfredi R; Borderi M; Rossi N; Conti M; Mancini R; Viale P
    AIDS Res Hum Retroviruses; 2017 Jul; 33(7):632-638. PubMed ID: 28088884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
    Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
    Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
    Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
    Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of raltegravir in HIV-1 management.
    Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
    Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
    Fun A; Leitner T; Vandekerckhove L; Däumer M; Thielen A; Buchholz B; Hoepelman AIM; Gisolf EH; Schipper PJ; Wensing AMJ; Nijhuis M
    Retrovirology; 2018 Jan; 15(1):1. PubMed ID: 29304821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
    Else LJ; Taylor S; Back DJ; Khoo SH
    Antivir Ther; 2011; 16(8):1139-47. PubMed ID: 22155898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
    Gutierrez-Valencia A; Chacón-Mora N; Ruiz-Valderas R; Ben-Marzouk-Hidalgo OJ; Torres-Cornejo A; Viciana P; Lopez-Cortes LF
    Medicine (Baltimore); 2015 Oct; 94(43):e1743. PubMed ID: 26512567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial.
    Vispo E; Barreiro P; Maida I; Mena A; Blanco F; Rodríguez-Novoa S; Morello J; Jimenez-Nacher I; Gonzalez-Lahoz J; Soriano V
    HIV Clin Trials; 2010; 11(4):197-204. PubMed ID: 20974575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA.
    Rossetti B; Meini G; Bianco C; Lamonica S; Mondi A; Belmonti S; Fanti I; Ciccarelli N; Di Giambenedetto S; Zazzi M; De Luca A
    J Clin Virol; 2017 Jun; 91():18-24. PubMed ID: 28395180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.
    Lê MP; Valantin MA; Assoumou L; Soulie C; Le Mestre S; Weiss L; Yazdanpanah Y; Molina JM; Bouchaud O; Raffi F; Reynes J; Calvez V; Marcelin AG; Costagliola D; Katlama C; Peytavin G;
    Pharmacotherapy; 2019 Apr; 39(4):514-520. PubMed ID: 30815916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients.
    Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Lin KY; Huang YC; Su YC; Liu WC; Hung CC
    Int J Antimicrob Agents; 2019 Jul; 54(1):35-42. PubMed ID: 30905695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.
    Monteiro P; Perez I; Laguno M; Martínez-Rebollar M; González-Cordon A; Lonca M; Mallolas J; Blanco JL; Gatell JM; Martínez E
    J Antimicrob Chemother; 2014 Mar; 69(3):742-8. PubMed ID: 24128667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
    Pradat P; Durant J; Brochier C; Trabaud MA; Cottalorda-Dufayard J; Izopet J; Raffi F; Lucht F; Gagnieu MC; Gatey C; Jacomet C; Vassallo M; Dellamonica P; Cotte L;
    J Antimicrob Chemother; 2016 Nov; 71(11):3235-3241. PubMed ID: 27432606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Role of the new molecules in antiretroviral therapy. Position of raltegravir].
    Arribas JR
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C; Tribut O
    Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.
    Cooper CL; van Heeswijk RP
    HIV Med; 2007 Jan; 8(1):1-7. PubMed ID: 17305925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.